[O2–01–02]: THE AMYLOID RISK SCORE: AN ACCURATE AND CROSS‐VALIDATED METHOD THAT PREDICTS CEREBRAL β‐AMYLOIDOSIS

preclinical AD in between. Evaluating SCD-plus criteria as indicators of preclinical AD, we found that age>60 (Odds Ratio 7.7(95%CI 1.738.9)) and APOE e4 (OR 4.8(1.6-15.0)) were independently associated with preclinical AD, while caregiver report (OR 1.9(0.6-5.7)) and onset<5 years (OR 0.9(0.3-2.7)) were not. Conclusions:The SCIENCe project extensively investigates factors potentially related to the subjective experience of cognitive decline. Evaluation of the first 151 participants revealed a heterogeneous group, with besides preclinical AD also subthreshold psychiatric features, and roughly half having no clear origin of complaints. Furthermore, some, but not all, SCD-plus criteria were associated with preclinical AD.